{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:47:30Z","timestamp":1771879650414,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2005,3,24]],"date-time":"2005-03-24T00:00:00Z","timestamp":1111622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002On\u2010demand treatment may be an alternative in the long\u2010term treatment of non\u2010severe gastro\u2010oesophageal reflux disease in patients with frequent symptomatic relapses.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To compare the efficacy of on\u2010demand treatment with rabeprazole 10\u2003mg versus continuous treatment in the long\u2010term treatment of patients with frequent symptomatic relapses of mild to moderate gastro\u2010oesophageal reflux disease.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002This randomized, open\u2010label study enrolled patients diagnosed with non\u2010erosive reflux disease or oesophagitis grade 1 or 2 (Savary\u2013Miller classification) reporting frequent symptomatic relapses (requiring \u22652 courses of antisecretory therapy during the previous year), whose intensity is rated at least moderate (&gt;2 on a 5\u2010point Likert scale). After a 4\u2010week selection phase with rabeprazole 10\u2003mg once daily, patients reporting symptom relief (Likert score \u22642) were randomized to receive either rabeprazole 10\u2003mg continuous treatment or on\u2010demand treatment for 6\u2003months. The main evaluation criterion was the rate of symptom relief (scored on the Likert scale) after 6\u2003months.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002One hundred and seventy\u2010six patients were enrolled in the 4\u2010week selection phase (men, 53%; mean age, 49\u2003years; non\u2010erosive reflux disease, 36.4%; gastro\u2010oesophageal reflux disease 1, 53.4%; gastro\u2010oesophageal reflux disease 2, 10.2%). Rabeprazole relieved symptoms in 88.6% of patients. Of this group, 152 were randomized to the comparative phase to receive rabeprazole 10\u2003mg continuous treatment (once daily) or on\u2010demand treatment (continuous treatment, <jats:italic>n<\/jats:italic>\u2003=\u200381; on\u2010demand treatment, <jats:italic>n<\/jats:italic>\u2003= 71). At month 6 (end point), the symptom relief rate was slightly higher for patients in the continuous treatment group compared with those in the on\u2010demand treatment group: 86.4% versus 74.6%, respectively. This difference was not statistically significant (<jats:italic>P<\/jats:italic>\u2003=\u20030.065). For the overall quality of life score, there was no difference between the continuous treatment and on\u2010demand treatment groups (86.25 and 84.94). Mean daily consumption of rabeprazole was significantly lower in the on\u2010demand treatment group versus the continuous treatment group (0.31 tablets versus 0.96 tablets; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001).<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold> :\u2002On\u2010demand therapy with rabeprazole 10\u2003mg provides an alternative to continuous therapy in patients with mild to moderate gastro\u2010oesophageal reflux disease suffering from frequent symptomatic relapses.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2005.02413.x","type":"journal-article","created":{"date-parts":[[2005,3,24]],"date-time":"2005-03-24T11:16:14Z","timestamp":1111662974000},"page":"805-812","source":"Crossref","is-referenced-by-count":53,"title":["Long\u2010term treatment of gastro\u2010oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on\u2010demand treatment compared with continuous treatment"],"prefix":"10.1111","volume":"21","author":[{"given":"B.","family":"Bour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.\u2010L.","family":"Staub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Chousterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Labayle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Nalet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Nouel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Tocque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bonnot\u2010Marlier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,3,24]]},"reference":[{"key":"e_1_2_18_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70025-8"},{"key":"e_1_2_18_3_2","first-page":"1139","article-title":"Epid\u00e9miologie du reflux gastro\u2010oesophagien en m\u00e9decine g\u00e9n\u00e9rale: facteurs pr\u00e9dictifs de la consommation de soins sur un an","volume":"23","author":"Vallot T","year":"1999","journal-title":"Gastroenterol Clin Biol"},{"key":"e_1_2_18_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05912.x"},{"key":"e_1_2_18_5_2","first-page":"56","article-title":"Gastroesophageal reflux in adults: diagnosis and treatment. Conclusions of Consensus Conference: long text. Organized by the French National Society of Gastroenterology and Belgian Royal Society of Gastroenterology\/Flemish Society of Gastroenterology. French Society of Digestive Surgery. French Society of Digestive Endoscopy. French Society of Pharmacology [In French]","volume":"23","year":"1999","journal-title":"Gastroenterol Clin Biol"},{"key":"e_1_2_18_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01206.x"},{"key":"e_1_2_18_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.17.s2.5.x"},{"key":"e_1_2_18_8_2","first-page":"463","article-title":"Factors influencing compliance in long\u2010term proton pump inhibitor therapy in general practice","volume":"49","author":"Hungin APS","year":"1999","journal-title":"Br J Gen Pract"},{"key":"e_1_2_18_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00564.x"},{"key":"e_1_2_18_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00943.x"},{"key":"e_1_2_18_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200208000-00008"},{"key":"e_1_2_18_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01999.x"},{"key":"e_1_2_18_13_2","first-page":"32","article-title":"Questionnaire de qualit\u00e9 de vie dans le reflux gastro\u2010oesophagien","volume":"23","author":"Amouretti M","year":"1999","journal-title":"Gastroenterol Clin Biol"},{"key":"e_1_2_18_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(03)00010-8"},{"key":"e_1_2_18_15_2","first-page":"A130","article-title":"Esomeprazole continuous versus on\u2010demand maintenance therapy in 1052 gastro\u2010oesophageal reflux disease patients: similar satisfaction but superior quality of life for once daily treatment [Abstract]","volume":"52","author":"Engels LGJB","year":"2003","journal-title":"Gut"},{"key":"e_1_2_18_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.4.481"},{"key":"e_1_2_18_17_2","first-page":"857","article-title":"On\u2010demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole","volume":"14","author":"Johnsson F","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"e_1_2_18_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01496.x"},{"key":"e_1_2_18_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262100-00006"},{"key":"e_1_2_18_20_2","volume-title":"Acid Related Diseases \u2013 Biology and Treatment","author":"Modlin IM","year":"1998"},{"key":"e_1_2_18_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02176.x"},{"key":"e_1_2_18_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00418.x"},{"issue":"1","key":"e_1_2_18_23_2","first-page":"S13","article-title":"Nonerosive reflux disease: part of the spectrum of gastro\u2010oesophageal reflux disease, a component of functional dyspepsia, or both? [Review]","volume":"13","author":"Quigley EM","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2005.02413.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2005.02413.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T17:44:09Z","timestamp":1697391849000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2005.02413.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,24]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1111\/j.1365-2036.2005.02413.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02413.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,24]]}}}